Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy

@article{Shami2003RecombinantAF,
  title={Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy},
  author={V. Shami and S. Caldwell and E. E. Hespenheide and K. Arseneau and S. Bickston and B. Macik},
  journal={Liver Transplantation},
  year={2003},
  volume={9}
}
  • V. Shami, S. Caldwell, +3 authors B. Macik
  • Published 2003
  • Medicine
  • Liver Transplantation
  • Severe coagulopathy in fulminant hepatic failure (FHF) is difficult to correct by conventional means. Recombinant activated factor VII (rFVIIa) is an antihemophilic factor that has shown promise in treating coagulopathy in liver disease. Our aim is to review our experience with rFVIIa in treating the coagulopathy of FHF and compare these results with those of conventional therapy. Fifteen patients with FHF who met King's College criteria for orthotopic liver transplantation were studied. All… CONTINUE READING
    213 Citations
    FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: A report of four cases
    • 94
    • PDF
    The use of recombinant factor VIIa in liver diseases
    • 22
    Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand
    • 9
    Activated recombinant factor VII in orthotopic liver transplantation.
    • 33
    Recombinant FVIIa in children with liver disease.
    • 17

    References

    SHOWING 1-10 OF 27 REFERENCES
    The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
    • 34
    Coagulopathy of liver disease
    • 39
    Recombinant activated factor VII as a universal haemostatic agent.
    • U. Hedner
    • Medicine
    • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
    • 1998
    • 122
    Clinical experience with recombinant factor VIIa.
    • 211
    Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study
    • B. Macik, C. Lindley, +7 authors H. Roberts
    • Medicine
    • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
    • 1993
    • 65